(Q37886653)

24 August 2017

1 reference

title

Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis (English)

1 reference

24 August 2017

0 references

1 reference

Andrew L Mammen

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

8 June 2011

1 reference

24 August 2017

published in

Nature Reviews Neurology

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

343-354

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2011.63

24 August 2017

exact match

0 references

cites work

Polymyositis and dermatomyositis (second of two parts)

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Myopathy with antibodies to the signal recognition particle: clinical and pathological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Paraneoplastic necrotizing myopathy: clinical and pathological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Paraneoplastic necrotizing myopathy: a rare disorder to be differentiated from polymyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Sporadic inclusion body myositis: pathogenic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Theories of the pathogenesis of inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Spontaneous electrical muscle fiber activity in polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Muscle biopsy findings in inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Polymyositis, dermatomyositis and inclusion-body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Fidelity of gamma-glutamyl transferase (GGT) in differentiating skeletal muscle from liver damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Polymyositis and dermatomyositis (first of two parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Magnetic resonance imaging of the idiopathic inflammatory myopathies: structural and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Skeletal muscle involvement in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The heart and cardiac conduction system in polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The heart in dermatomyositis and polymyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Pulmonary disease in polymyositis/dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Opioid use by patients in an orthopedics spine clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The chromatin remodeler Mi-2beta is required for CD4 expression and T cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Antagonistic interactions between Ikaros and the chromatin remodeler Mi-2beta determine silencer activity and Cd4 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Myositis specific autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Human autoantibodies reactive with the signal-recognition particle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

A comprehensive description of muscle symptoms associated with lipid-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Muscle symptoms associated with statins: a series of twenty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Polymyositis induced or associated with lipid-lowering drugs: five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

3-hydroxy 3-methylglutaryl coenzyme A reductase increase is essential for rat muscle differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Endothelial inclusions in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The childhood type of dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Endothelial cell activation and neovascularization are prominent in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Vascular pathology in dermatomyositis and anatomic relations to myopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The nature of the principal type 1 interferon-producing cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Dermatomyositis and type 1 interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Cancer and myositis: new insights into an old association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The role of MRI in the assessment of polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

A novel autoantibody to a 155-kd protein is associated with dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The idiopathic inflammatory myopathies: spectrum of MR imaging findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Cost-effectiveness of MR imaging in evaluating polymyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Cutaneous photosensitivity in dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Idiopathic inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Cardiac manifestations in polymyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Interstitial Pneumonitis in Association with Polymyositis and Dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Autoantibodies to aminoacyl-tRNA synthetases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Description of a serological reaction characteristic of polymyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Analysis of the Mi-2 autoantigen of dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The association between Mi-2 antibodies and dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Antibody to signal recognition particle in polymyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Progressive myopathy with up-regulation of MHC-I associated with statin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Microvascular changes in early and advanced dermatomyositis: a quantitative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Microvascular deposition of complement membrane attack complex in dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Formation of tubuloreticular inclusions in mitogen-stimulated human lymphocyte cultures by endogenous or exogenous alpha-interferon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.63

Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease

31 March 2020

1 reference

12 December 2020

An update on HLA association of Mi-2 autoantibodies: the association with a tryptophan at position 9 of the HLA-DRbeta chain is strong but not absolute

1 reference

12 December 2020

Dermatopolymyositis and other connective tissue diseases: a review of 105 cases

1 reference

12 December 2020

Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis

1 reference

12 December 2020

Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature

1 reference

12 December 2020

1 reference

12 December 2020

Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies.

1 reference

12 December 2020

Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis

1 reference

12 December 2020

ECG abnormalities in polymyositis

1 reference

12 December 2020

Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis

1 reference

12 December 2020

Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis

1 reference

12 December 2020

Dermatomyositis with normal creatine kinase and elevated aldolase levels.

1 reference

12 December 2020

Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2',5' oligoadenylate synthetase induction

1 reference

12 December 2020

Calcification is rare in adult-onset dermatopolymyositis

1 reference

12 December 2020

Fatal Pulmonary Involvement in Dermatomyositis

1 reference

12 December 2020

Inflammatory disorders of muscle. Cardiac abnormalities

1 reference

12 December 2020

Severe polymyositis with simvastatin use

1 reference

12 December 2020

Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies

1 reference

12 December 2020

Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies.

1 reference

12 December 2020

Amyopathic dermatomyositis: a review

1 reference

12 December 2020

Dermatomyositis: immunopathologic study of skin lesions.

1 reference

12 December 2020

A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups

1 reference

12 December 2020

Classification criteria for the idiopathic inflammatory myopathies

1 reference

12 December 2020

Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon

1 reference

12 December 2020

Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes

1 reference

12 December 2020

Myocardial involvement in polymyositis

1 reference

12 December 2020

Interstitial lung disease in dermatomyositis: clinicopathological study

1 reference

12 December 2020

Classification criteria for polymyositis and dermatomyositis

1 reference

12 December 2020

Monoclonal antibodies to human leucocyte antigens in polymyositis and muscular dystrophy

1 reference

12 December 2020

Immune-mediated necrotizing myopathy associated with statins

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2011.63

1 reference

24 August 2017

1 reference